We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Newly-Developed Enzyme Could Treat Mysterious Multisystem Complications of COVID-19

By HospiMedica International staff writers
Posted on 11 Aug 2020
Illustration
Illustration
Scientists have developed a first-in-class DNASE1L3 enzyme analog, NTR-441, that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19.

The enzyme has been developed by Neutrolis (Cambridge, MA, USA), a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body. NTR-441, an engineered analog of the natural NET-destroying enzyme DNASE1L3, is the world's first investigational drug that can be systemically delivered to accurately target NETs.

NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. NETs are sticky, web-like structures made of chromatin—DNA studded with structural proteins—and expelled by suicidal neutrophils. NETs block air sacs and blood vessels in the lungs, trigger hyperinflammation and blood clotting (thrombosis), potentially causing irreversible end-organ damage and death.

Several independent investigators have observed NETs in the lungs of autopsied COVID-19 patients, and observed that NETs biomarkers in patient blood correlate with the clinical severity of COVID-19. In patients with severe COVID-19, the circulating levels of DNASE1L3 are not adequate to counteract the rapid and systemic formation of NETs. NTR-441 has the potential to systemically clear NETs in the vasculature and end organs like the lungs in patients suffering from severe COVID-19.

"We believe NETs are the common factor that explains the mysterious multisystem complications of COVID-19," said Toby Fox, Ph.D., Chief Executive Officer and Co-Founder of Neutrolis. "Our lead compound, NTR-441, and other molecules from our Chromatinase platform are the only drugs currently in development that could systemically remove NETs from the body. Thanks in part to competitive funding from the National Institutes of Health (R43HL150944), we will test whether NTR-441 is effective in ARDS, the most lethal manifestation of COVID-19."

Related Links:

Neutrolis

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Mammography System (Analog)
MAM VENUS
New
Antimicrobial Mat
MULTIMAT

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more